{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:48:52Z","timestamp":1789858132610,"version":"4.0.1"},"reference-count":35,"publisher":"The Journal of Rheumatology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To review our experiences with high-dose infliximab (IFX) to treat juvenile idiopathic arthritis (JIA). We routinely use high doses of IFX (10\u201320 mg\/kg) in children with recalcitrant or highly active JIA. Although biologics have revolutionized treatment of JIA, many patients have active disease despite therapy. Studies have shown benefits of high-dose IFX in several conditions, including inflammatory bowel disease, psoriasis, and idiopathic uveitis. The safety and effectiveness of high-dose IFX have not been evaluated in JIA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We performed a retrospective review of children with JIA who received IFX \u2265 10 mg\/kg. We recorded all serious adverse events (SAE), medically important infections, and infusion reactions. We also recorded the physician global assessment of disease activity (MD global) and active joint count (AJC) at initiation of high-dose IFX and 3, 6, and 12 months thereafter.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Fifty-eight subjects received a total of 1064 infusions over 95 person-years. There were a total of 9 SAE (9.5\/100 person-yrs), 7 of which were potentially related to therapy, and 6 infusion reactions (0.5%), none constituting anaphylaxis. Statistically significant improvements were observed in the AJC (median 0, range 0\u201331, vs 2, 0\u201339) and MD global (12, 2\u201331, vs 22, 5\u201380) over the first year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>High-dose IFX appears safe in the management of JIA. Future prospective controlled studies are necessary to evaluate its safety and efficacy.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.130133","type":"journal-article","created":{"date-parts":[[2013,8,16]],"date-time":"2013-08-16T02:55:33Z","timestamp":1376621733000},"page":"1749-1755","source":"Crossref","is-referenced-by-count":54,"title":["High Doses of Infliximab in the Management of Juvenile Idiopathic Arthritis"],"prefix":"10.3899","volume":"40","author":[{"given":"Ajay","family":"Tambralli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Beukelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Weiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Prescott","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy Quentin","family":"Cron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Laurence","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2013,8,15]]},"reference":[{"key":"2018112909320190000_40.10.1749.1","first-page":"394","article-title":"Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis","volume":"30","author":"Bowyer","year":"2003","journal-title":"J Rheumatol"},{"key":"2018112909320190000_40.10.1749.2","first-page":"1382","article-title":"Radiographic and clinical outcome in early juvenile rheumatoid arthritis and juvenile spondyloarthropathy: A 3-year prospective study","volume":"33","author":"Selvaag","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909320190000_40.10.1749.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.2.198"},{"key":"2018112909320190000_40.10.1749.4","doi-asserted-by":"publisher","DOI":"10.2165\/11532610-000000000-00000"},{"key":"2018112909320190000_40.10.1749.5","unstructured":"US Food and Drug Administration . Drug approval reports by month. [Internet. Accessed June 20, 2013.] Available from: www.accessdata.fda.gov\/Scripts\/cder\/DrugsatFDA\/"},{"key":"2018112909320190000_40.10.1749.6","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.547575"},{"key":"2018112909320190000_40.10.1749.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.100354"},{"key":"2018112909320190000_40.10.1749.8","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20460"},{"key":"2018112909320190000_40.10.1749.9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2125.2010.03760.x","article-title":"Appropriate infliximab infusion dosage and monitoring: Results of a panel meeting of rheumatologists, dermatologists, and gastroenterologists","volume":"71","author":"de Vries","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"2018112909320190000_40.10.1749.10","doi-asserted-by":"crossref","first-page":"765380","DOI":"10.5402\/2012\/765380","article-title":"High dose infliximab in the treatment of refractory uveitis: Does dose matter?","volume":"2012","author":"Sukumaran","year":"2012","journal-title":"ISRN Rheumatol"},{"key":"2018112909320190000_40.10.1749.11","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20177"},{"key":"2018112909320190000_40.10.1749.12","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22902"},{"key":"2018112909320190000_40.10.1749.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04523.x"},{"key":"2018112909320190000_40.10.1749.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.01.005"},{"key":"2018112909320190000_40.10.1749.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100995"},{"key":"2018112909320190000_40.10.1749.16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"2018112909320190000_40.10.1749.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.27511"},{"key":"2018112909320190000_40.10.1749.18","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-8-23"},{"key":"2018112909320190000_40.10.1749.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.27506"},{"key":"2018112909320190000_40.10.1749.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.34458"},{"key":"2018112909320190000_40.10.1749.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.34348"},{"key":"2018112909320190000_40.10.1749.22","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909320190000_40.10.1749.23","first-page":"234","article-title":"Juvenile idiopathic arthritis classification criteria: Loopholes and diagnosis software","volume":"34","author":"Behrens","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909320190000_40.10.1749.24","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R"},{"key":"2018112909320190000_40.10.1749.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.24777"},{"key":"2018112909320190000_40.10.1749.26","doi-asserted-by":"publisher","DOI":"10.1186\/ar3386"},{"key":"2018112909320190000_40.10.1749.27","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-003-0040-8"},{"key":"2018112909320190000_40.10.1749.28","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W"},{"key":"2018112909320190000_40.10.1749.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.07.005"},{"key":"2018112909320190000_40.10.1749.30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033486"},{"key":"2018112909320190000_40.10.1749.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90628-9"},{"key":"2018112909320190000_40.10.1749.32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/03009742.2010.517546","article-title":"Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis","volume":"40","author":"Trachana","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"2018112909320190000_40.10.1749.33","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.256"},{"key":"2018112909320190000_40.10.1749.34","doi-asserted-by":"publisher","DOI":"10.1002\/art.22214"},{"key":"2018112909320190000_40.10.1749.35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh074"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.130133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T18:28:36Z","timestamp":1543516116000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.130133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,15]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,10,1]]},"published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.3899\/jrheum.130133"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.130133","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,15]]}}}